Cetuximab Plus Dalpicilib in Patients With HPV Negative, PD-1 Resistant R/M HNSCC
Status:
Recruiting
Trial end date:
2026-01-01
Target enrollment:
Participant gender:
Summary
This study is the first clinical study in PD-1 resistant patients with head and neck squamous
cell carcinoma with drugs targeting EGFR signaling pathway combined with CDK4/6 inhibitors,
which explores the new combination therapies urgently needed in clinical practice and lays a
foundation for subsequent studies, with important scientific research significance and
clinical value.
Phase:
Phase 2
Details
Lead Sponsor:
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University